Sun et al. demonstrated that the clinical outcomes of KRAS-mutant NSCLC patients varied in response to ICI-based first-line treatment to some extent with different KRAS mutation subtypes and co-mutations. Here, KRAS is linked to non-small cell lung carcinoma.